A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis  by Okura, Yuji et al.
A Clinical and Histopathologic
Comparison of Cardiac Sarcoidosis
and Idiopathic Giant Cell Myocarditis
Yuji Okura, MD, PHD,* G. William Dec, MD, FACC,§ Joshua M. Hare, MD, FACC,
Makoto Kodama, MD,¶ Gerald J. Berry, MD,# Henry D. Tazelaar, MD,† Kent R. Bailey, PHD,‡
Leslie T. Cooper, MD, FACC*
Rochester, Minnesota; Boston, Massachusetts; Baltimore, Maryland; Niigata, Japan; and Stanford, California
OBJECTIVES The goal of this study was to determine the prognostic value of clinical data available at
presentation and histology in cardiac sarcoidosis (CS) and idiopathic giant cell myocarditis
(IGCM).
BACKGROUND The prognosis of patients with nonischemic cardiomyopathy is partly dependent on the
histologic diagnosis. Survival in IGCM is poor. The prognosis of a histologically related
entity, cardiac sarcoidosis (CS), is less well established, and the prognostic value of the
distinction between CS and IGCM on endomyocardial biopsy (EMB) is unknown.
METHODS We identified 115 patients from the Multicenter IGCM Registry with CS (n  42) and
IGCM (n  73). We compared the clinical data for these two groups using Cox
proportional-hazards models to assess the association between histologic diagnosis and
survival. In order to determine whether histologic features could reliably differentiate these
two entities, two cardiac pathologists semiquantitatively graded the inflammatory infiltrate
components and compared the results between groups.
RESULTS Black race was more frequent in the CS group (31% vs. 4%, p  0.0001). Syncope and
atrioventricular block were also more frequently observed in CS than IGCM (31% vs. 5%, p
 0.0002 and 50% vs. 15%, p  0.0001, respectively). Left-sided heart failure was more
common in IGCM (40% vs. 64%, p  0.013). In CS patients diagnosed by EMB, the
five-year transplant-free survival after diagnosis was 69.8% versus 21.9% for IGCM (p 
0.0001, log-rank test). In multivariate models, presentation with heart failure predicted
IGCM, and presentation with heart block or more than nine weeks of symptoms predicted
CS. Eosinophils, myocyte damage, and foci of lymphocytic myocarditis were more frequent
in IGCM, while granulomas and fibrosis were more frequent in CS.
CONCLUSIONS Transplant-free survival is better for patients with CS than for IGCM diagnosed by EMB.
Presentation with heart failure predicted IGCM, and presentation with heart block or more
than nine weeks of symptoms predicted CS. (J Am Coll Cardiol 2003;41:322–8i) © 2003
by the American College of Cardiology Foundation
The prognosis of patients with nonischemic cardiomyopa-
thy is partly dependent on the histologic diagnosis (1). For
example, transplant-free survival is much worse for patients
with idiopathic giant cell myocarditis (IGCM) than lym-
phocytic myocarditis (2). An unanswered question is
whether IGCM is part of the spectrum of cardiac sarcoid-
osis (CS) (or idiopathic granulomatous myocarditis) or a
distinct clinical and histologic entity (3–5). Reports of
IGCM and CS consist of isolated cases and small single-
center autopsy series (6). Idiopathic giant cell myocarditis
and CS are sometimes grouped together in clinical series
(7). Because a systematic clinical and histologic comparison
of these entities has not been reported, the value of their
distinction remains uncertain.
Idiopathic giant cell myocarditis is a rapidly fatal disorder
characterized by the presence of multinucleated giant cells
and a lymphocytic inflammatory infiltrate, associated with
myocyte necrosis (8). If noncaseating granulomas are
present and infectious etiologies are excluded, the diagnosis
is idiopathic granulomatous myocarditis or CS (6). This
histologic distinction is not based on proven clinical or
mechanistic differences between these disorders.
Cardiac sarcoidosis and IGCM are rare and present with
similar symptoms. No single center has accumulated a
sufficient number of cases diagnosed during life to compare
their natural histories (9). Clinical findings of congestive
heart failure (CHF), ventricular arrhythmias, and heart
block are associated with both CS and IGCM (2,10–12).
The relative frequency of cardiac events in these disorders is
not known. To assess the value of the histologic distinction
of CS and IGCM, we compared the presentation and
clinical course of CS and IGCM in 115 patients with
histologically confirmed disease.
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METHODS
Patient selection. Five of the participating centers (“core
centers”) in the Giant Cell Myocarditis Registry with large
referral populations and expertise in CS and IGCM sys-
tematically searched the surgical and autopsy pathology
records to gather all cases of pathologically confirmed CS
and IGCM. These centers are Mayo Clinic Rochester
(MCR), Minnesota; Johns Hopkins Hospital (JHH), Bal-
timore, Maryland; Massachusetts General Hospital
(MGH), Boston, Massachusetts; Stanford University Med-
ical Center (SUMC), Stanford, California; and Niigata
University Hospital (NUH), Niigata, Japan. The dates of
case diagnosis are as follows: MCR (January 1982 to
November 1999), JHH (March 1987 to December 1997),
MGH (November 1980 to July 1996), SUMC (March 1983
to July 1999), NUH (May 1985 to February 1997).
In addition to the analysis of all cases at these core
centers, pathologically confirmed cases of CS and IGCM
referred to the registry from other centers were included in
a separate analysis. The distribution of cases and method of
diagnosis at core and non-core centers is described in Table
1. The “non-core” centers include those participating in the
original Giant Cell Myocarditis Registry (see December 18
JACC issue on the internet www.cardiosource.com/
jacc.html for online Appendix ) (2). The cases of idiopathic
giant cell myocarditis in the original registry were solicited
through study announcements placed in Circulation (13),
the Journal of the American College of Cardiology (14), the
American Heart Journal (15), the American Journal of Cardi-
ology (16), and the Journal of Heart and Lung Transplanta-
tion (17), as well a thorough direct mailing to the directors
of transplantation centers participating in the United Net-
work for Organ Sharing and to other cardiovascular centers
worldwide.
Investigators completed a case report form requesting
anonymous historical data on the medical history, present-
ing symptoms, cardiac rhythm, and treatment. Respondents
were asked to list test results that excluded other causes of
myocarditis. Outcomes including death, heart transplant,
and date of last follow-up were obtained. Two patients were
excluded from analysis; both had concomitant ischemic
cardiomyopathy, and one patient had cor pulmonale that
prevented accurate timing of symptom onset.
Pathologic analysis. The initial diagnosis of CS or IGCM
was based on review of the tissue at the time of entry into
the trial based on published criteria (8) by the local
pathologist. Among these, 83 had the diagnosis confirmed
by either H.D.T. or G.J.B. The diagnosis of CS required
the presence of at least one nonnecrotizing granuloma, with
or without foci of lymphocytic myocarditis, necrosis, or the
presence of isolated giant cells. The diagnosis of IGCM
required the presence of a widespread inflammatory infil-
trate with multinucleated giant cells in association with
myocyte damage (Fig. 1). The presence of a nonnecrotizing
granuloma alone in this background was insufficient to
classify a case as CS if the degree of necrosis was judged to
be out of proportion of the degree of granulomatous
inflammation. Cases that did not fulfill these criteria were
excluded from analysis.
At the time of the current study, 74 of the specimens were
available for review. Although it was our impression that the
previously described criteria were sufficient for separating
these two entities histologically, there has been an ongoing
debate about whether they are, in fact, two or one disease.
Therefore, we thought that a direct comparison of histo-
logic features seen in the pathologic material should be
performed. To this end, one of two cardiac pathologists
(G.J.B. or H.D.T.) then re-reviewed the available material
(endomyocardial, surgical, or autopsy) and scored the spec-
imens on a semiquantitative four-point scale (from 0 to 3)
for multinucleated giant cells, granulomas, necrosis, lym-
phocytes, eosinophils, fibrosis, and foci of lymphocytic
myocarditis.
To assess for consistency of scoring among pathologists,
both pathologists scored the same 10 specimens indepen-
dently. This analysis revealed that there was no significant
difference in scoring between pathologists (p values for the
Table 1. Distribution of Cases and Method of Diagnosis
Idiopathic Giant Cell Myocarditis
No. of Cases (%)
Core Center (%) Non-Core Center (%) All (%)
Biopsy 16 (57) 22 (49) 38 (52)
Explant 4 (14) 11 (24) 15 (21)
Autopsy 8 (29) 9 (20) 17 (23)
Others* 0 (0) 3 (7) 3 (4)
Total 28 (100) 45 (100) 73 (100)
Cardiac Sarcoidosis
No. of Cases (%)
Core Center (%) Non-Core Center (%) All (%)
Biopsy 25 (71) 4 (57) 29 (69)
Explant 5 (14) 3 (43) 8 (19)
Autopsy 4 (11) 0 (0) 4 (10)
Others* 1 (3) 0 (0) 1 (2)
Total 35 (100) 7 (100) 42 (100)
*Others included three left ventricular apexes during assist device placement in
idiopathic giant cell myocarditis and one atrial specimen at maze operation in cardiac
sarcoidosis.
Abbreviations and Acronyms
CHF  congestive heart failure
CI  confidence interval
CS  cardiac sarcoidosis
EMB  endomyocardial biopsy
IGCM  idiopathic giant cell myocarditis
JHH  Johns Hopkins Hospital
MCR  Mayo Clinic Rochester
MGH  Massachusetts General Hospital
NUH  Niigata University Hospital
SUMC  Stanford University Medical Center
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comparison of scores for each parameter measured ranged
from 0.11 to 0.90). The pathologists agreed completely or
disagreed by one point (on the four-point scale) for
multinucleated giant cells (100%), granulomas (88%), ne-
crosis (100%), lymphocytes (100%), eosinophils (88%),
fibrosis (100%), and foci of lymphocytic myocarditis
(100%).
Idiopathic giant cell myocarditis and CS had distinct
histologic features. Cardiac sarcoidosis specimens had more
granulomas (p  0.0001) and fibrosis (p  0.0002), while
the IGCM specimens had more necrosis (p  0.0217), foci
resembling lymphocytic myocarditis (p  0.0427), and
eosinophils (p 0.0001). There were equivalent numbers of
giant cells in the CS and IGCM specimens (Fig. 2).
Statistical analysis. The demographics of CS and IGCM
cases were compared using the Wilcoxon rank-sum test for
continuous variables, and the chi-square or Fisher exact test
for dichotomous variables. Fisher exact test was used when
the expected count was 5. Multivariate comparison of the
two diseases was done by logistic regression modeling. The
demographics of cases (within disease category) at the five
core and the non-core centers were also compared to assess
presence or absence of referral bias in the core center
populations. Finally, the patient characteristics, including
the presenting symptoms, time from onset of symptoms to
presentation, time from onset to diagnosis, and the presence
and types of arrhythmia and heart block at presentation for
all cases of CS and IGCM from core and non-core centers
were compared.
The primary end point for assessing outcome was heart
transplantation or death. Transplant-free survival rates in
the CS and IGCM cases were compared using the log-rank
test. Because of the makeup of cases including cases diag-
nosed at biopsy, explant, or autopsy, two different compar-
isons of survival were performed. First, survival from date of
endomyocardial biopsy (EMB) diagnosis to death, trans-
plant, or last follow-up was compared in all biopsy-
diagnosed cases (n  67). This analysis is mostly free from
assumptions, because patients had to have an established
diagnosis to enter the study. However, it was also deemed of
interest to compare survival from onset of symptoms in all
patients (n  115). This latter analysis makes the assump-
tion that patients who were ultimately diagnosed, whether
by biopsy, explanted heart, or autopsy were representative of
Figure 1. (A) Cardiac sarcoidosis characterized by coalescence of granulomatous elements along lymphatic pathways of the myocardial interstitium (H&E
 60). (B) High-power magnification showing well-formed nonnecrotizing granulomas composed of epithelioid histiocytes and giant cells embedded in
callagenous stroma. Mononuclear inflammatory cells and fibroblasts surround the granulomas (H&E 400). (C) Idiopathic giant cell myocarditis (IGCM)
showing widespread necrosis of myocytes by a dense cellular infiltrate (H&E  100). (D) High-power magnification of IGCM displaying giant cells,
lymphocytes, histiocytes, eosinophils, and damaged myocytes (H&E  400).
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all those who contract each respective disease. Each of these
two analyses was repeated on the subset of patients diag-
nosed at the core centers.
In the comparative survival analysis from biopsy diagno-
sis, log-rank tests were supplemented by proportional haz-
ards models to adjust for potential confounding variables.
Variables considered were age, gender, race, symptoms at
presentation, and duration of symptoms. Because of the
highly skewed distribution of time from onset of symptoms
to diagnosis, this variable was converted into an ordinal scale
(14 days, 15 to 30, 31 to 179, 180 days). In the
comparative survival analysis from symptom onset, age,
gender, and race were considered as adjusting variables.
RESULTS
Patient characteristics. The demographics for patients
from core and non-core centers are described in Table 2.
The mean (SD) age of the 42 patients with CS was 44.7
 10.8 years at time of onset of symptoms. This was not
significantly different from the age at symptom onset for the
73 patients with IGCM (42.5  13.2). The ages of CS and
IGCM patients at core and non-core centers were similar.
The percentage of men was not significantly higher in
patients with CS (62%) than in patients with IGCM (52%)
in the total cohort (p  0.31) and at the five core centers
(CS, 66%; IGCM, 46%, p  0.13). Although the percent-
age of blacks in CS was higher than in IGCM at the five
core centers (p  0.001, Table 2), CS and IGCM were
diagnosed most often in whites. The racial composition of
our study population may reflect the demographics of the
referral populations and not actual differences in the disease
prevalence.
The duration from symptom onset to presentation and
symptom onset to diagnosis were greater for CS than
IGCM (Table 2; CS, 5.5  12.1 months vs. IGCM, 1.2 
4.4 months, p  0.01, and CS, 29.7  53.3 months vs.
IGCM, 5.0  10.0 months, p  0.005, respectively). This
difference was observed at both core and non-core centers.
Left-sided CHF was more common at presentation in
IGCM than in CS (Table 3, p  0.0127), although the left
ventricular ejection fraction was similar in the two groups (n
 85; IGCM, 29.1%  11.2% vs. CS, 30.7%  15.5%).
Syncope and atrioventricular block were more common in
CS (syncope, p  0.0002 and atrioventricular block, p 
0.0001). Ventricular tachycardia was commonly observed in
both groups at presentation.
The use of pacemakers was more common in the CS
group than in the IGCM group (Table 4, 45% vs. 25%, p
0.05); however, the use of intraaortic balloon counterpulsa-
tion (2% vs. 34%, p  0.001), ventricular assist devices (0%
vs. 16%, p  0.05), and heart transplantation (29% vs. 51%,
p  0.05) was more common in the IGCM group. When
core and non-core centers treatments for IGCM were
compared, the use of intraaortic balloon counterpulsation
(18% vs. 44%, p  0.05), ventricular assist devices (4% vs.
24%, p  0.05), and heart transplantation (32% vs. 62%, p
 0.05) was more common in the non-core centers.
Survival. The transplant-free survival probability was 10%
in the IGCM group (n  73) and 60.5% in the CS group
(n  42) at five years after symptom onset (p  0.0001 by
log-rank test, Fig. 3A). The survival five years after biopsy
diagnosis for the 67 patients diagnosed by EMB (Fig. 3B)
was also worse in the IGCM group (21.9%) than the CS
group (69.8%, p  0.0001 by log-rank test). When the
Figure 2. Histologic scores for 75 cases of idiopathic giant cell myocarditis (IGCM) and cardiac sarcoidosis (CS). Scores were compared using the Wilcoxon
rank-sum test. *p  0.05; †p  0.01. Open bar  IGCM; solid bar  CS.
Table 2. Patients Characteristics
Characteristics
Idiopathic Giant
Cell Myocarditis
(n  73)
Cardiac
Sarcoidosis
(n  42)
Age at onset (yr) 42.5  13.2 44.7  10.8
Time; onset to hospital present (mo) 1.2  4.4 5.5  12.1*
Time; onset to diagnosis (mo) 5.0  10.0 29.7  53.3†
Male gender (%) 38 (52) 26 (62)
Ethnicity
White race (%) 55 (75) 15 (36)‡
Black race (%) 3 (4) 13 (31)‡
Asian race (%) 5 (7) 2 (5)
Other races (%) 4 (6) 2 (5)
Unknown (%) 6 (8) 10 (24)
Plus-minus values are means  SD. *p  0.01; †p  0.005; ‡p  0.001.
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latter analysis was further limited to the 41 patients diag-
nosed by EMB at core centers (Fig. 3C), the same survival
difference was observed (35.7% vs. 75.7%, p  0.0013 by
log-rank test).
In a Cox proportional hazards model, we analyzed
variables that might be independent predictors of
transplant-free survival after biopsy diagnosis (at all centers).
In a forward stepwise model that included candidate vari-
ables of age at diagnosis, gender, white race, presentation
with heart failure, duration of symptoms, and IGCM, the
selected model variables were IGCM, age, and presentation
with heart failure.
In this model, age was negatively associated with risk,
that is, younger people had worse transplant-free survival
(hazard ratio, 0.755 [confidence interval {CI}, 0.579 to
0.985]; p  0.03). However, when stratified by disease
group, age was not significantly associated with worse
transplant-free survival (CS, p  0.18; IGCM, p  0.11).
The positive effect of CHF symptoms on higher risk was
only marginal (hazard ratio, 3.70 [CI, 0.80 to 17.1]; p 
0.088). Because IGCM patients tended to be younger and
more likely to present with CHF, the adjustment for these
variables reduced, but did not eliminate, the significance of
IGCM histology (hazard ratio, 3.42 [CI, 1.32, 8.85]; p 
0.0099). If all the candidate variables were added into the
model whether significant or not, the effect of IGCM was
rendered of marginal significance (p  0.073). This was
largely because the inclusion of “duration of symptoms” in
the model, so dramatically different in the two diseases,
inflated the standard error for IGCM as well as reducing the
effect somewhat.
In a logistic model, we estimated baseline clinical vari-
ables that would predict IGCM among patients diagnosed
by biopsy or nontransplant surgical pathology (before trans-
plant or death) diagnosis (Table 5). In this model, heart
failure at presentation and white ethnicity predicted
IGCM (p  0.0001 and p  0.0005), while atrioven-
tricular block and time from symptom onset of more than
nine weeks predicted CS (p  0.0002 and p  0.0313).
If the analysis was restricted to those patients who were
diagnosed by EMB at core centers, the only variables that
predicted IGCM on biopsy were time from symptom
onset to biopsy of 9 weeks (p  0.004) and white race
(p  0.002).
Table 3. Symptoms at Hospital Presentation
Characteristics
Idiopathic Giant Cell Myocarditis Cardiac Sarcoidosis
Core Centers
(n  28)
All
(n  73)
Core Centers
(n  35)
All
(n  42)
Symptom at hospital presentation
Left-sided heart failure (%) 16 (57) 47 (64) 16 (46) 17 (40)*
Right-sided heart failure (%) 1 (4) 2 (3) 2 (6) 2 (5)
Both-sided heart failure (%) 8 (29) 21 (29) 5 (14) 7 (17)
Syncope (%) 1 (4) 4 (5) 8 (23)* 13 (31)†
Palpitation (%) 2 (7) 8 (11) 5 (14) 7 (17)
Chest pain (%) 6 (21) 14 (19) 6 (17) 6 (14)
Sudden death (%) 0 (0) 2 (3) 2 (6) 2 (5)
Arrhythmia
Sinus bradycardia (%) 1 (4) 2 (3) 3 (9) 4 (10)
Atrioventricular block (%) 5 (18) 11 (15) 17 (49)* 21 (50)†
First degree (%) 3 (11) 5 (7) 8 (23) 9 (21)
Type I second degree (%) 0 (0) 0 (0) 0 (0) 0 (0)
Type II second degree (%) 0 (0) 0 (0) 0 (0) 1 (2)
Complete (%) 2 (7) 6 (8) 9 (26) 11 (26)
Ventricular tachycardia (%) 8 (29) 21 (29) 8 (23) 11 (26)
Ventricular fibrillation (%) 0 (0) 2 (3) 2 (6) 2 (5)
Core centers and all centers in cardiac sarcoidosis were compared with those in idiopathic giant cell myocarditis respectively. *p
 0.05; †p  0.001.
Table 4. Additional Care to Conventional Therapy
Characteristics
Idiopathic Giant Cell Myocarditis Cardiac Sarcoidosis
Core Centers
(n  28)
All
(n  73)
Core Centers
(n  35)
All
(n  42)
Corticosteroid administration (%) 19 (68) 40 (55) 27 (77) 31 (74)
Pacemaker implantation (%) 8 (29) 18 (25) 15 (43) 19 (45)*
Cardioverter defibrillator implantation (%) 6 (21) 9 (12) 8 (23) 10 (24)
Intraaortic balloon pump insertion (%) 5 (18) 25 (34) 1 (3)* 1 (2)†
Ventricular assist device insertion (%) 1 (4) 12 (16) 0 (0) 0 (0)*
Heart transplantation (%) 9 (32) 37 (51) 8 (23) 12 (29)*
Core centers and all centers in cardiac sarcoidosis were compared with those in idiopathic giant cell myocarditis, respectively. *p
 0.05; †p  0.001.
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DISCUSSION
The results of this study strongly suggest that CS and
IGCM are distinct clinicopathologic entities. The data
suggest that despite high rates of heart block, heart failure,
and tachyarrhythmias, survival in CS is much better than in
IGCM. Presentation with heart failure predicted IGCM,
and presentation with heart block or more than nine weeks
of symptoms predicted CS.
Our observation that CS and IGCM have distinct natural
histories suggests that they may also be pathophysiologically
distinct. As the etiology of these disorders is poorly defined,
it remains unclear whether the clinical differences relate to
different environmental exposures or to variable host immu-
nologic factors. For example, the spatial and familial clus-
tering of sarcoidosis (18) has not been observed in IGCM.
Nonetheless, there are gross similarities in immunologic
response. Experimental IGCM (19,20) and sarcoidosis are
both associated with an early infiltrate of CD4-positive T
cells with a T helper type 1 response, secreting interleukin-2
and interferon-. At a later stage of lesion evolution, a
dominant T helper type 2 response may lead to fibrosis.
Despite a similar reduction in ejection fraction, left-sided
CHF and use of ventricular assist devices were more
frequent in IGCM than in CS. We speculate that the
difference in disease phenotype may be, in part, due to the
prominence of eosinophil products in the IGCM lesions.
Eosinophil granules contain major basic protein, eosinophil
peroxidase, eosinophil cationic protein, and eosinophil-
derived neurotoxin. Eosinophils are also capable of choe-
moattractant production, including proteins such as
platelet-activating factor and eotaxin, as well as cytokine
production. Eosinophilic proteins such as eosinophil perox-
idase are also capable of producing cytotoxic substances
including hydrogen peroxide and halide acids (21). Idio-
pathic giant cell myocarditis is also a more acute process
than CS in which there is little time for adaptation to
myocardial dysfunction. A novel finding from our study is
that the number of multinucleated giant cells were similar in
CS and IGCM, suggesting that these cells are not primarily
involved in the disease phenotype.
Our data are limited by the selected patient cohort and
the observational study design. Because sarcoidosis is a
multisystem disease with a heterogenous clinical course, our
findings may not apply to patients with predominantly lung
or other organ involvement. Indeed, only 33% of our CS
cohort had evidence of extracardiac involvement. Other
studies suggest that there is a gender difference in extrapul-
monary sarcoid in Japanese patients (22) that may limit the
applicability of our findings to different ethnic groups.
However, the relatively large number of cases, the inclusion
of all pathologically diagnosed cases at the core centers, and
the independent interpretation of histologic slides by cardiac
pathologists in most cases strengthen our observations of
natural history.
Although cases diagnosed by biopsy yield the most useful
clinical data, this analysis is subject to greatest bias due to
the low sensitivity of biopsy for sarcoidosis and the exclusion
of critically ill patients who might die or undergo transplan-
tation without a biopsy. Realizing the limitations of this
analysis, we ascertained all cases of pathologically confirmed
CS from the core centers, including autopsy, explanted
heart, or other surgical pathology specimens. We estimated
Table 5. Logistic Regression Model for Variables Associated
With Independent Predictors of Idiopathic Giant Cell
Myocarditis
Variables
Hazard Ratio
(95% CI) p Value
Presenting with heart failure 57.62 (7.94–418.10) 0.0001
White ethnicity 8.90 (2.59–30.56) 0.0005
Atrioventricular blockage 0.20 (0.06–0.70) 0.0121
Time from onset to diagnosis
More than 26 weeks 0.07 (0.02–0.29) 0.0002
More than 9 weeks 0.12 (0.02–0.83) 0.0313
CI  confidence interval.
Figure 3. Kaplan-Meier curves illustrating transplant-free survival in
cardiac sarcoidosis (CS) and idiopathic giant cell myocarditis (IGCM)
patients. (A) Time from symptom onset for 115 subjects from all centers.
(B) Time from endomyocardial biopsy in 67 patients from all centers. (C)
Time from endomyocardial biopsy in 41 patients at five core centers. All
survival comparisons are by log-rank test.
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transplant-free survival from symptom onset in the entire
cohort, as well as from time of diagnosis in the biopsy
diagnosed subjects, in order to compare the outcome of
patients with granulomas on biopsy to all patients with CS.
The additional analyses of patients diagnosed at autopsy or
explantation sought to account for survivor selection bias in
the biopsy cohort. The differences between CS and IGCM
in time to presentation and time to diagnosis may be due to
the more indolent natural history of CS.
The question of which, if any, of the variables are
legitimately considered as confounding in the multivariate
analyses is uncertain. If the question is “which disease has a
worse prognosis,” then one might consider the unadjusted
analysis the preferable one. If the question is “which disease
has worse prognosis for a person of a given age, gender, race,
with these presenting symptoms, and duration of symp-
toms,” then the adjusted analysis is to be preferred. To
equate symptoms and duration of symptoms between
groups is perhaps to match patients in a way that is not
representative of each disease.
Although there has been debate as to whether IGCM
and CS are separate disorders, the results of the pathologic
analysis in this study show significant histologic differences
between CS and IGCM, which could be clinically useful.
Patients with IGCM in our series had a more fulminant
clinical course with a shorter time from symptom onset to
death or transplantation. Patients with IGCM more fre-
quently required mechanical circulatory support. Despite
the aggressive clinical course of IGCM in our series, CS was
more frequently associated with high-grade heart block or
pacemaker requirement. Further research is required to
determine if treatment can favorably alter the natural history
of these disorders.
Reprint requests and correspondence: Dr. Leslie T. Cooper, Jr.,
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APPENDIX
The members of the Multicenter Giant Cell Myocarditis
Study Group were as follows:
Massachusetts General Hospital, Boston, Massachusetts:
G. W. Dec, J. T. Fallon, and J. Southern; Stanford
University Hospital, Stanford, California: J. S. Schroeder
and J. Friedman; Johns Hopkins Hospital, Baltimore,
Maryland: J. M. Hare and R. H. Hruban; Rikshospitalet,
Oslo, Norway: S. Simonsen; Rush-Presbyterian-St. Luke’s
Medical Center, Chicago, Illinois: M. Johnson; Hospital of
the University of Pennsylvania, Philadelphia, Pennsylvania:
E. Loh, B. Drachman, C. Reynolds, and M. van de Rijn;
Alfred Hospital, Prahan, Australia: M. Richardson, S. K.
Tang, and J. S. Pedersen; Sahlgrenska University Hospital,
Goteborg, Sweden: C.-H. Bergh, A. Oldfors, and U.
Nystrom; Virginia Commonwealth University/Medical
College of Virginia, Richmond, Virginia: M. Flattery, D. E.
Tolman, and M. M. Grimes; University of Vienna, Vienna,
Austria: R. Ullrich and R. Horvat; Baptist Medical Center
of Oklahoma, Oklahoma City, Oklahoma: D. K. C. Coo-
per; Brigham and Women’s Hospital, Boston, Massachu-
setts: S. Davis, M. Givertz, and G. Winters; Centre
Hospitalier Universitaire Vaudois, Lausanne, Switzerland:
J. J. Goy and C. Genton; Elmhurst Hospital Center,
Elmhurst, New York: N. E. Kantrowitz and G. Turi;
Harefield Hospital, London, United Kingdom: M. Yacoub
and A. Pomerance; Hospital Germans Trias I Pujol, Bar-
celona, Spain: A. Ariza; Hospital Henri Mondor, Paris,
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France: D. Tixier; Herzzentrum Bad Krozingen, Bad Kroz-
ingen, Germany: N. Bruns and C. Ihling; Instituto de
Cardiologica y Cirugia Cardiovascular-Fundacion Favaloro,
Buenos Aires, Argentina: S. V. Perrone and R. R. Favaloro;
Mayo Clinic, Rochester, Minnesota: L. J. Olson and W. D.
Edwards; Columbia Hospital at Medical City, Dallas,
Texas: J. Hunt, J. M. Vidal, and W. J. Esber; Mid America
Heart Institute, Kansas City, Missouri: D. R. Bresnahan,
N. D. Long, and R. T. O’Kell; Newark Beth Israel Medical
Center, Newark, New Jersey: M. J. Zuker and L. T. Boral;
Presbyterian Hospital, Albuquerque, New Mexico: D. San-
sonetti, C. Moore, and J. H. Spigel; Presbyterian-St. Luke’s
Hospital, Denver, Colorado: J. Narrod, J. Small, and K. R.
Holloman; Prince Charles Hospital, Chermside, Australia:
A. Galbraith; Royal National Heart and Lung Institute,
London, United Kingdom: M. N. Shepherd; Saint Thomas
Hospital, Nashville, Tennessee: K. Biersack and C. M.
Davis; Sentara Norfolk General Hospital, Norfolk, Vir-
ginia: J. M. Herre and L. Ladaga; Split Clinical Hospital,
Split, Croatia: S. Polic; St. Elizabeth Hospital Medical
Center, Youngstown, Ohio: P. E. Hill; State University of
New York at Buffalo, Buffalo, New York: S. Graham, J. S.
Schwartz, and C. F. Celik; Sutter Memorial Hospital,
Sacramento, California: S. I. Stark; Honolulu Medical
Group, Honolulu, Hawaii: T. Hoffmann and K. Tonaki;
University of Alabama at Birmingham, Birmingham, Ala-
bama: R. B. Bourge; Cleveland Clinic Foundation, Cleve-
land, Ohio: N. B. Ratliff; University of Calgary-Foothills
Hospital, Calgary, Alberta, Canada: D. Issac, S. Agarwal,
and W. Lester; University of California at San Diego, La
Jolla, California: L.T. Cooper; University of Kansas Med-
ical Center, Kansas City, Missouri: S. B. Gollub and O.
Tawfik; University of Pittsburgh Medical Center, Pitts-
burgh, Pennslyvania: S. Murali; University of South Florida
College of Medicine, Tampa, Florida: G. B. Cintron and S.
Brantley; Washington University School of Medicine, St.
Louis, Missouri: M. W. Rich; Hospital, Helsinki, Finland:
M. Nieminen; Niigata University of Medicine, Niigata,
Japan: Y. Aizawa, A. Shibata; Social Health Insurance
Medical Center, Tokyo, Japan: K. Satomi, K. Kondou;
Northside Cardiology, P.C., Indianapolis, Indiana: M. N.
Walsh; Desert Hospital, Palm Springs, California: W. L.
Cooper, R. J. Rosser; South Texas Cardiovascular Consult-
ants, San Antonio, Texas: M. J. Wood.
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